Abstract:To the Editor: Tandem mass spectrometry (MS/MS)-based expanded newborn screening was first introduced in Pediatric Endocrinology/Genetics of Xin Hua Hospital in 2003. The screening is expected to detect genetic disorders leading to a secondary increase in blood phenylalanine (Phe) in newborns.[1] We reported a rare case in a Chinese infant with hyperphenylalaninemia (HPA) caused by phenylalanine hydroxylase (PAH) deficiency and neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). This constellation of two different metabolic pathway defects in one patient has not been reported previously. A 2-month-old Chinese infant boy was referred to Department of Pediatric Endocrinology/Genetics of Xin Hua Hospital for mild HPA (Phe 150 mmol/L) detected by newborn screening. He had persistent jaundice. The MS/MS analysis showed high blood Phe (220 mmol/L), citrulline (Cit) (168 mmol/L), methionine, and arginine levels, but normal Phe/tyrosine (Tyr). Gas chromatography-mass spectrometry showed elevated 4-hydroxyphenylpyruvic acid and 4-hydroxyphenyllactic acid in urine. The biochemical investigation revealed hyperbilirubinemia, high alpha-fetoprotein, and abnormal liver function. He had normal urinary pterins and dihydropteridine reductase activity. The patient was first diagnosed with NICCD and placed on a lactose-free formula containing medium-chain triglycerides at 2.5 months of age. However, biochemical marks and Cit level gradually returned to normal but elevated Phe (125–220 μmol/L) and Phe/Tyr (3.78–5.33) levels were noted since 8 months of age. Gene mutation analysis showed that this patient carries both known compound heterozygous mutations c.851del4/c.1638ins23 in SLC25A13 gene and mutations C.158G >A (p.R53H)/c. 728G >A (p.R243Q) in PAH gene. So he suffered from both PAH and citrin deficiencies. Urine pterin and dihydropteridine reductase activity analysis should be routinely performed to rule out BH4 deficiency. MS/MS analysis should be done to detect other genetic disorders leading to a secondary blood Phe increase in newborns with HPA according to the consensus.[2] PAH deficiency and NICCD are different autosomal recessive inborn errors. The PAH catalyzes the conversion of Phe to Tyr and its deficiency results in HPA [Figure 1a]. Citrin deficiency caused by SLC25A13 mutation is another disorder of the urea cycle [Figure 1b]. Cit is transported out from mitochondrion and bound to aspartate by argininosuccinate synthase, and aspartate is provided by the mitochondrial transporter citrin.[3] A newborn with citrin deficiency can manifest intrahepatic cholestasis and has elevated Cit and other amino acids (secondary to liver lesion).Figure 1: Metabolic pathways – (a) Metabolic pathway of phenylalanine; (b) Pathway of urea cycle.The mutations p.R243Q and p.R53H in PAH gene produce <10% and 80% of the normal PAH activity, respectively.[4] Our patient with both mutations had mild HPA without treatment. He also carries two most common mutations c.851del4/c.1638ins23 in SLC25A13 gene in China.[5] This rare case provided two important points for pediatric physicians: (1) Citrin deficiency that can lead to secondary high Phe levels should be ruled out for HPA by MS/MS analysis, and (2) if the blood Phe and Phe/Tyr are persistently elevated when Cit level returns to normal after treatment in an NICCD patient, she/he may also have PAH deficiency, and a gene mutation analysis is recommended to confirm the diagnosis. Financial support and sponsorship This study was supported by a grant from The National Key Technology R and D Program (No. 2012BAI09B00). Conflicts of interest There are no conflicts of interest.

Mutation analysis of FAH gene in patients with tyrosinemia type 1

Identification and Functional Characterization of a Novel Homozygous Intronic Variant in the Fumarylacetoacetate Hydrolase Gene in a Chinese Patient with Tyrosinemia Type 1.

[Clinical Features and Genetic Analysis of a Child with Acute Form of Tyrosinemia Type I Due to a Novel Variant of FAH Gene].

Analysis of clinical data and genetic mutations in three Chinese patients with tyrosinemia type Ⅰ

Screening for Hereditary Tyrosinemia and Genotype Analysis in Newborns

Thyrotropin Receptor and Thyroid Transcription Factor-1 Genes Variant in Chinese Children with Congenital Hypothyroidism.

Hereditary tyrosinemia type I–associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate

Clinical, Biochemical, and Molecular Characteristics of Filipino Patients with Tyrosinemia Type 1

Mutation spectrum of Tyrosinemia type I in Iran, A retrospective cohort study

Clinical and genetic analysis for a Chinese family with hereditary fructose intolerance

Four-hydroxyphenylpyruvic acid oxidase deficiency with normal fumarylacetoacetase: a new variant form of hereditary hypertyrosinemia

[Tyrosine Hydroxylase Deficiency: a Case of Autosomal Recessive Dopa-Responsive Dystonia].

Fumarylacetoacetate Hydrolase Knock-Out Rabbit Model for Hereditary Tyrosinemia Type 1

Clinical Phenotype and Genetic Mutation of Fatty Acid Hydroxylase - Associated Neurodegeneration: Analysis of Four Cases

Novel HPD Mutation P.a244v Compound with P.t219m Causing Tyrosinemia Type III in a Chinese Girl and Review of the Genotype–phenotype Spectrum

A Novel Tyrosine Hydroxylase Variant in a Group of Chinese Patients with Dopa-Responsive Dystonia.

R233H Mutation in Patients with Tyrosine Hydroxylase Deficiency and Corresponding Phenotypes: a Study of Four Cases and Literature Review.

Clinical and Molecular Characterization of Patients with Fructose 1,6-Bisphosphatase Deficiency

Phenylalanine Hydroxylase Deficiency and Citrin Deficiency in a Chinese Infant.

Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease

[Genetic Diagnosis of Fructose-1, 6-Bisphosphatase Deficiency: a Case Report].